Antifibrotic in interstitial lung diseases: When, where, and how long?

被引：3
|
作者：
Rai, Deependra K. [1 ]
Tripathi, Suryakant [2 ]
机构：
[1] AIIMS, Dept Pulm Med, Patna, Bihar, India
[2] KJMU, Dept Pulm Med, Lucknow, Uttar Pradesh, India
来源：
LUNG INDIA | 2022年 / 39卷 / 06期
关键词：
IDIOPATHIC PULMONARY-FIBROSIS; FORCED VITAL CAPACITY; DOUBLE-BLIND; PIRFENIDONE; NINTEDANIB; EFFICACY; SAFETY; UPDATE;
D O I：
10.4103/lungindia.lungindia_283_22
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：491 / 494
页数：4
相关论文
共 50 条
  • [1] Use of antifibrotic Drugs in interstitial Lung Disease
    Kreutz, Claus-Peter
    Gesierich, Wolfgang
    Behr, Juergen
    Kneidinger, Nikolaus
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2022, 147 (21) : 1383 - 1389
  • [2] Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases
    Dsouza, Kevin G.
    Surolia, Ranu
    Kulkarni, Tejaswini
    Li, Fu Jun
    Singh, Pooja
    Zeng, Huaxiu
    Stephens, Crystal
    Kumar, Abhishek
    Wang, Zheng
    Antony, Veena B.
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [3] What is new in the treatment of interstitial lung diseases
    Sotiropoulou, Vasilina
    Karampitsakos, Theodoros
    Katsaras, Matthaios
    Papaioannou, Ourania
    Tsiri, Panagiota
    Sampsonas, Fotios
    Tzouvelekis, Argyrios
    PNEUMON, 2023, 36 (02)
  • [4] Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
    Torrisi, Sebastiano Emanuele
    Kahn, Nicolas
    Waelscher, Julia
    Sarmand, Nilab
    Polke, Markus
    Lars, Kehler
    Eichinger, Monika
    Heussel, Claus Peter
    Palmucci, Stefano
    Sambataro, Francesca Maria
    Sambataro, Gianluca
    Sambataro, Domenico
    Vancheri, Carlo
    Kreuter, Michael
    BMC PULMONARY MEDICINE, 2019, 19 (01)
  • [5] Antifibrotic therapies in rheumatoid arthritis associated interstitial lung disease
    Bes, Cemal
    Koybasi, Gizem
    Icacan, Ozan Cemal
    Mutlu, Melek Yalcin
    Yildirim, Fatih
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2022, 9 (03) : 176 - 179
  • [6] The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease
    Boleto, Goncalo
    Avouac, Jerome
    Allanore, Yannick
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
  • [7] Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis
    Yang, Mei
    Tan, Yuying
    Yang, Ting
    Xu, Dan
    Chen, Mei
    Chen, Lei
    PLOS ONE, 2025, 20 (02):
  • [8] Management of patients with fibrosing interstitial lung diseases
    Morrow, Lee E.
    Hilleman, Daniel
    Malesker, Mark A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (03) : 129 - 139
  • [9] Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
    Choi, Won-Il
    PRECISION AND FUTURE MEDICINE, 2021, 5 (01): : 31 - 40
  • [10] The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease
    Sarkar, Paroma
    Avram, Cristina
    Chaudhuri, Nazia
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (10) : 1001 - 1008
12345